Nuvalent (NUVL) to Post Quarterly Earnings on Thursday

Nuvalent (NASDAQ:NUVL) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Nuvalent to post earnings of ($1.44) per share and revenue of $0.2450 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period in the prior year, the firm posted ($1.18) earnings per share. On average, analysts expect Nuvalent to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Nuvalent Stock Performance

Shares of NASDAQ:NUVL opened at $123.96 on Tuesday. Nuvalent has a 12-month low of $71.13 and a 12-month high of $123.99. The business’s fifty day simple moving average is $118.56 and its 200-day simple moving average is $108.32. The company has a market capitalization of $9.79 billion, a PE ratio of -20.46 and a beta of 1.14.

Insiders Place Their Bets

In other Nuvalent news, insider Deborah Ann Miller sold 5,500 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $107.84, for a total value of $593,120.00. Following the completion of the sale, the insider directly owned 59,634 shares in the company, valued at approximately $6,430,930.56. This trade represents a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO James Richard Porter sold 30,000 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $88.53, for a total value of $2,655,900.00. Following the completion of the sale, the chief executive officer owned 324,879 shares of the company’s stock, valued at approximately $28,761,537.87. This trade represents a 8.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 90,471 shares of company stock valued at $9,762,529. 5.02% of the stock is currently owned by corporate insiders.

Institutional Trading of Nuvalent

Institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. acquired a new stake in Nuvalent during the 3rd quarter worth about $107,794,000. Wellington Management Group LLP grew its stake in Nuvalent by 46.0% during the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after purchasing an additional 724,491 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Nuvalent by 32.9% in the fourth quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock valued at $221,826,000 after purchasing an additional 545,542 shares during the period. Invesco Ltd. increased its holdings in shares of Nuvalent by 1,201.4% in the fourth quarter. Invesco Ltd. now owns 439,300 shares of the company’s stock valued at $44,189,000 after purchasing an additional 405,543 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Nuvalent by 18.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,146,938 shares of the company’s stock worth $215,962,000 after purchasing an additional 336,518 shares during the last quarter. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. UBS Group downgraded Nuvalent from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $138.00 to $124.00 in a research report on Wednesday, June 10th. Cantor Fitzgerald lowered shares of Nuvalent from an “overweight” rating to a “neutral” rating in a research report on Tuesday, June 9th. Truist Financial downgraded shares of Nuvalent from a “buy” rating to a “hold” rating and cut their price objective for the stock from $140.00 to $124.00 in a research report on Tuesday, June 9th. Leerink Partners set a $165.00 price objective on shares of Nuvalent in a research report on Wednesday, June 3rd. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $124.00 price objective (up from $116.00) on shares of Nuvalent in a research note on Tuesday, June 9th. Four investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $127.73.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.